Bernstein analyst William Pickering initiated coverage of Ionis Pharmaceuticals with an Underperform rating and $31 price target. The company’s ASO technology appears to underperform RNAi on knockdown depth and/or dosing frequency, the analyst tells investors in a research note. The firm says Ionis has experienced "quite a few setbacks over the years," and that this trend will continue "until we have strong evidence to the contrary."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IONS:
- Ionis Pharmaceuticals: FDA accepts NDA for eplontersen
- RXDX vs. IONS: Which Biotech Stock is Better?
- Ionis Pharmaceuticals price target lowered to $27 from $34 at SVB Securities
- Ionis Pharmaceuticals price target lowered to $40 from $44 at Barclays
- Ionis Pharmaceuticals sees FY23 revenue $575M, consensus $672.18M